Feature

Renowned interventional cardiologist dies of COVID-19


 

The interventional cardiology community is mourning the loss of Anthony “Tony” Gershlick, MBBS, who died Nov. 20 of COVID-19. He was 69 years old.

Dr. Gershlick was a “talented, dedicated and much loved colleague,” reads a statement issued by the University of Leicester (England), where he was affiliated for more than 3 decades.

Dr. Gershlick, a consultant cardiologist at Glenfield Hospital and professor of interventional cardiology, University of Leicester, passed away in the intensive care unit of the hospital where he worked.

Nishan Canagarajah, PhD, president and vice-chancellor, University of Leicester, said Dr. Gershlick “left an indelible mark on the life of the University. He will be remembered with great affection by all and will be sorely missed.”

In 2017, Dr. Gershlick was honored with the inaugural British Cardiovascular Intervention Society (BCIS) Lifetime Achievement Career Award for his “outstanding contribution to the specialty of coronary intervention.”

Gershlick was a pioneer in the field of percutaneous coronary intervention. He was the first UK cardiologist to implant a drug-eluting stent and a bioabsorbable stent, according to an article in the European Heart Journal.

Throughout his career, Dr. Gershlick had been involved in “practice-changing” research that changed the way patients are treated and led to national and international guidelines. He was the UK lead for more than 10 international trials, the university said.

“Tony was determined to push the boundaries of clinical care, to make a difference for his patients, and indeed, patients around the world,” said Philip Baker, DM, FMedSci, head of the College of Life Science, University of Leicester.

Andrew Furlong, medical director at the University Hospitals of Leicester, noted that Dr. Gershlick was “deeply committed to the training and development of junior doctors and registrars and known for his dedication to his field and his patients. He made a difference to many, many lives.”

According to the university, Dr. Gershlick had been working in non-COVID environments since April and was doing much of his work via virtual consultations. He took on cases from other consultants to help during the pandemic and had been working “tirelessly” to provide continuing care to cardiology patients.

The news of Dr. Gershlick’s passing prompted an outpouring of sadness and remembrances of him on Twitter.

A version of this article originally appeared on Medscape.com.

Recommended Reading

Is the tide turning on the ‘grubby’ affair of EXCEL and the European guidelines?
MDedge Cardiology
COMPARE CRUSH: Crushed prehospital prasugrel misses mark in STEMI
MDedge Cardiology
PARTNER registry valve-in-valve outcomes reassuring at 5 years
MDedge Cardiology
PCI success vs. meds only in diabetes may depend on LDL-C control
MDedge Cardiology
Virtual AHA 2020 may influence template for postpandemic scientific sessions
MDedge Cardiology
Clopidogrel bests ticagrelor head-to-head for elective PCI in ALPHEUS
MDedge Cardiology
New-onset AFib common but unrecognized in the month after cardiac surgery
MDedge Cardiology
Boston Scientific bails on Lotus Edge aortic valve system
MDedge Cardiology
Stenotic lesion outcomes better if fractional flow reserve guides PCI
MDedge Cardiology
Potential new option: 1-month DAPT post DES, then aspirin alone
MDedge Cardiology